anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Vitamin D is necessary to develop healthy lungs and other organs early in life. Most infants born before 28 weeks' gestation have low vitamin D levels at birth and a limited intake during the first month. Enteral vitamin D supplementation is inexpensive and widely used. The appropriate supplementation regimen for extremely preterm infants is controversial, and the effect of different regimens on their blood levels and outcomes is unclear.
METHODS: Randomized, blinded comparative effectiveness trial to compare two vitamin D supplementation regimens for inborn infants <28 weeks gestation or <1000 g birth weight at a large academic center in the United States. Infants are stratified by birth weight and randomized within 96 h after birth to either routine supplementation (400 IU/day with established feedings) or increased supplementation (800 IU/day with any feedings) during the first 28 days after birth. We hypothesize that the higher and early vitamin D dose (800 IU/day with early feeding) compared to placebo plus routine dose (400 IU/day with established feeding) will substantially increase total 25-hydroxyvitamin D3 levels measured as state-of-art at 1 month, reduce respiratory support at 36 weeks' postmenstrual age (on an ordinal scale predictive of later adverse outcomes), and improve or at least not worsen other important secondary outcomes. The infants in the study will follow up at 22-26 months' corrected age (~2 years) with blinded certified examiners to evaluate neurodevelopmental outcomes. The sample size of a minimum of 180 infants provides >90% power to detect a >95% posterior probability of a 33% increase in serum 25-hydroxy vitamin D3 and >80% power to detect a >80% posterior probability of a relative risk decrease of 20% of reducing respiratory support by intention-to-treat Bayesian analyses using a neutral prior probability.
DISCUSSION: Our study will help clarify the uncertain relationship of vitamin D supplementation and its associated serum metabolites to clinical outcomes of extremely preterm infants. Confirmation of our hypotheses would prompt reconsideration of the supplementation regimens used in extremely preterm infants and justify a large multicenter study to verify the generalizability of the results.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05459298. Registered on July 14, 2022.
PURPOSE: To obtain a medicine suppressing growth of virus, T-cell of adult leukemia or retrovirus such as AIDS virus, etc., and sterilizing without side effect by including an alkali extract of Asparasus linearis as an active component. CONSTITUTION: This antiviral medicine contains an alkali extract of Asparasus linearis belonging to family Leguminosae as an active component. Said extract is obtained by extracting stems, leaves or roots of Asparasus linearis preferably with hot water, drying and extracting with an alkali such as sodium hydroxide. The extraction with hot water is performed in a manner that Asparasus linearis is immersed in 5-1000times of water, extracted at 70-100 deg.C for about from 10min. to 4hrs, dried under sunlight or indoor for 1-3days, 5-500times of 0.5-5% alkali solution is added and stirred with shaking at 10-60 deg.C for about from 30min. to 10hrs. In the case of using the medicine as a drink, taking of each 1-10mg/L solution to the total 20-500mL/day is preferable.
Families, and spouses in particular, have been shown to play important roles in all aspects of health care, especially when family members are recovering from the trauma of sudden illness or an accident such as a brain injury. A limited body of evidence suggests couple therapy provides patients and their spouses with the opportunity to explore the experience of trauma as it relates to becoming physically disabled within the context of intimate relationships. Being in close contact and emotionally connected to a person who has experienced trauma becomes a chronic stressor that can cause family members to experience trauma symptoms themselves. This phenomenon is termed secondary traumatic stress. For example, children can mimic a parent's trauma responses through identification with the parent or direct training. This is a specific type of secondary traumatisation transmitted intergenerationally.

The research about individuals who have a traumatic brain injury (TBI) and the impact of the injury on family functioning has outlined a number of challenges including: psychological distress, particularly anxiety and depression, among caregivers; disruptions in family functioning; and the impact on relationships including caregiver burden. Furthermore, among the most difficult conditions for couples to deal with are those involving cognitive impairment.

Hold Me Tight is a couples enrichment program that is based on the Emotionally Focused Therapy (EFT) approach to working with couples. EFT is an empirically supported treatment that arose out of emotion theory and attachment theory. It views emotions as centrally important in the experience of self, in both adaptive and maladaptive functioning, and in therapeutic change. From the EFT perspective change occurs by means of awareness, regulation, reflection, and transformation of emotion taking place within the context of an empathetically attuned relationship. There is significant research on this approach and it has been found that 70-75% of couples move from distress to recovery and that the gains are sustained for months to years following the end of treatment. As such, EFT is an evidence based treatment protocol.
ABSTRACT OF THE DISCLOSURE           Method and apparatus for use in the diag-nostic analysis of a liquid specimen through binding assays.  The apparatus includes a rigid body having an elongated, shallow well formed in it, with a plurality of elongated strips, preferably in the form of cotton threads, stretched across the well in spaced relationship and generally perpendicular to the well's longitudinal axis.  Each thread is coated with a separate binding conjugate such as an antigen or allergen.  A cover plate that includes a thin plastic layer and an overlaying thin metallic layer covers the well to form an enclosed chamber having a specific volume.   The metallic layer includes a separate elongated aperture in alignment with each coated thread.  A liquid specimen is introduced into the chamber through one of two ports, for incubation with the coated threads, after which the specimen is removed and the reaction that occurred on each thread is deter-mined.
Chronic granulomatous disease (CGD) is a primary immunodeficiency disease caused by molecular defects in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. p67phox-CGD is an autosomal recessive CGD, which is caused by a defect in the cytosolic components of NADPH oxidase, p67phox, encoded by NCF2. We previously established a flow cytometric analysis for p67phox expression, which allows accurate assessment of residual protein expression in p67phox-CGD. We evaluated the correlation between oxidase function and p67phox expression, and assessed the relevancy to genotypes and clinical phenotypes in 11 patients with p67phox-CGD. Reactive oxygen species (ROS) production by granulocytes was evaluated using dihydrorhodamine-1,2,3 (DHR) assays. p67phox expression was evaluated in the monocyte population. DHR activity and p67phox expression were significantly correlated (r = 0.718, p < 0.0162). Additionally, DHR activity and p67phox expression were significantly higher in patients carrying one missense variant in combination with one nonsense or frameshift variant in the NCF2 gene than in patients with only null variants. The available clinical parameters of our patients (i.e., age at disease onset, number of infectious episodes, and each infection complication) were not linked with DHR activity or p67phox expression levels. In summary, our flow cytometric analysis revealed a significant correlation between residual ROS production and p67phox expression. More deleterious NCF2 genotypes were associated with lower levels of DHR activity and p67phox expression. DHR assays and protein expression analysis by using flow cytometry may be relevant strategies for predicting the genotypes of p67phox-CGD.
This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID No.2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No.3; (iii) the minimal epitope from the amino acid sequence shown as SEQ ID No.4. (iv) the minimal epitope from the amino acid sequence shown as SEQ ID No. 5. (v) the minimal epitope from the amino acid sequence shown as SEQ ID No.6. (vi) the minimal epitope from the amino acid sequence shown as SEQ ID No.7. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
Participants will be randomized 1:1 to wear (A) the LiveMetric wristband on the first day and Bpro wristband on the second day or (B) Bpro wristband on the first day then LiveMetric wristband on the second day. The arm side (i.e., right or left) will be determined by the Aktiia cuffless blood pressure device randomization on the first day. For the second day, the Aktiia cuffless blood pressure device will be worn on the arm opposite the first day with the other device (LiveMetric versus Bpro) worn on the contralateral arm.
Variable domain murine T-cell receptor genes have been isolated and used to construct cloning and expression vectors. V α , V β  and single chain V α -V β  fragments have been expressed as secreted domains in  Escherichia coli  using the vectors. The domains are secreted into the culture supernatant in milligram quantities. The single domains and the single chain T-cell receptors are folded into β-pleated sheet structures similar to those of immunoglobulin variable domains. The secreted fragments may be useful for immunization to generate anti-clonotypic antibodies, in vaccination or for high resolution structural studies. The genes encoding these domains may also serve as templates for in vitro mutagenesis and improvement of affinities of the TCR fragments for their interaction with cognate peptide-MHC complexes.
PURPOSE:To provide a carcinostatic agent containing actinomycin S3 as an active component. CONSTITUTION:Actinomycin D and actinomycin S3 having antibacterial activity can be obtained from the cultured product of a bacterial strain KY 11634 (FERM-P No.4673). Actinomycins known as antibiotics include actinomycin D, C, C2, S3, etc. The actinomycin S3 (LD50: 0.35mg/kg, i.p.) having higher activity than the actinomycin D having antitumor activity is used as an active component for a carcinostatic agent. It is administered by intravenous injection, peritoneal infusion, etc. Preferable doses for intravenous injection or peritoneal infusion: 2-4mug/kg daily for continuous administration and 10-15mug/kg per dose for intermittent administration (once/7 days).
The invention relates to a medicament for treating esophageal cancer. China has a high esophagus cancer occurrence rate, the number of people who die from the esophagus cancer is only second to the number of people who die from the stomach cancer, and radiotherapy and chemotherapy which are mainly used to treat the esophagus cancer have large side effects. According to the invention, solanum nigrum, Solanum dulcamara, Duchesnea indica, goldhair hedyotis herb and Chinese sage herb into extract dry powder. The root of the pathomechanism of esophageal cancer lies in that the functions of the body decades due to weak Yang qi. Esophageal cancer is mainly treated by warming Yang, tonifying qi, strengthening vital energy and improving body functions. The treatment principle of traditional Chinese medicine is demonstrated in the invention. The medicine is capable of soothing liver, regulating qi, descending adverse qi, removing stasis, promoting blood circulation, removing stasis, softening hardness to dissipate stagnation, strengthening body resistance and archaeus, promoting the secretion of saliva or body fluid, moistening dryness, resolving phlegm, clearing heat, detoxifying, resisting cancer, relieving pain, warming Yang, tonifying qi and the like. Compared with other method for treating esophageal cancer, the medicine is relatively guaranteed and safe and has advantages of stable dose and component, convenience for oral administration, and obvious treatment effect.
Olmesartan, originally known for its antihypertensive properties, exhibits promising potential in addressing inflammation-mediated diseases. As an angiotensin II receptor blocker (ARB), Olmesartan influences pivotal pathways, including reactive oxygen species, cytokines, NF-κB, TNF-α, and MAPK. This suggests a viable opportunity for repurposing the drug in conditions such as ulcerative colitis, neuropathy, nephropathy, and cancer, as supported by multiple preclinical studies. Ongoing clinical trials, particularly in cardiomyopathy and nephropathy, suggest a broader therapeutic scope for Olmesartan. Repurposing efforts would entail comprehensive investigations using disease-specific preclinical models and dedicated clinical studies. The drug's established safety profile, wide availability, and well-understood ARB mechanism of action offer distinct advantages that could facilitate a streamlined repurposing process. In summary, Olmesartan's versatile impact on inflammation-related pathways positions it as a promising candidate for repurposing across various diseases. Ongoing clinical trials and the drug's favorable attributes enhance its appeal for further exploration and potential application in diverse medical contexts.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT. The major dose-limiting toxicities found in the Phase I studies have been pains in the feet and legs of 2 patients initially receiving 12 mg/kg/day and 12 patients receiving daily doses of 25.8 to 51.2 mg/kg; symptoms began 8 to 27 weeks after initiating ddI treatment. These neuropathy-like symptoms have generally not been associated with significant abnormalities in nerve conduction studies and patients have reported marked improvement in symptoms within 1 to 2 weeks of discontinuing ddI. Some patients have resumed ddI treatment at a reduced dose after resolution of their symptoms. Studies indicate that ddI remains active in the body for at least 12 hours. This indicates that benefits of ddI might be achieved with a low frequency of drug administration.

Patients are randomized to one of three ddI treatment groups; within each group, doses will be adjusted according to patient's weight at study entry. Stratification is by diagnosis of AIDS or AIDS related complex (ARC) and Medical Center. Data will be tabulated for the Data and Safety Monitoring Board at 3 month intervals.
PROBLEM TO BE SOLVED: To obtain the subject solution which is obtained by inexpensively and efficiently dissolving an easily oxidizable hydrophobic substance into a solution and is useful as an ophthalmic solution or the like by including and solubilizing the easily oxidizable hydrophobic substance in a specific size of micell with the use of a surfactant. SOLUTION: The objective solution is obtained by including and solubilizating (A) an easily oxidizable hydrophobic substance in (B) a micell with a size of 0.03-5 μm, preferably 0.05-0.5 μm, by adding (C) a surfactant and, when necessary, (D) a solution adjuvant, e.g. a salt, an alcohol, propylene glycol or the like, a stabilizer, a buffering agent, water or the like. As the component A, diphenhydramine, indometacin, a vitamin A (β-carotin or the like is included), a vitamin E (e.g. d-α-tocopherol acetate or the like) or the like is illustrated. As the component C, a nonionic surfactant, e.g. a polyoxyethylene-cured castor oil, a polyoxy-ethylene sorbitan fatty acid ester or the like, is preferably used.
Cervical spine tumor is a small-sample tumor disease with low incidence, great harm, and complex anatomical structure. It is very difficult to identify and classify benign and malignant cervical spine tumors clinically. The deep learning model we constructed in the early stage is suitable for the large number of cases. The imaging diagnosis of cervical spondylosis has a high accuracy rate and a good clinical application effect, but the accuracy rate is low for cervical spine tumors with a small number of cases. The reason may be that for tasks with limited amount of data, the traditional deep learning model is difficult to play an effective role. Based on this, we propose to construct a small sample-oriented deep learning model to assist clinicians in the diagnosis of cervical spine tumors in multi-modal imaging, and to evaluate the benign and malignant tumors. This research will not only improve the efficiency and efficiency of cervical spine tumor imaging diagnosis. Accuracy, to guide clinical personalized treatment, will also provide a basis for the clinical application of deep learning in the field of small samples, which has important clinical significance.
Participants receive ulevostinag 540 ug via intratumoral (IT) injection on Day 1 of every week for two 3-week cycles (Cycles 1-2), then on Day 1 of each 3-week cycle for up 33 cycles (Cycles 3-35), for a total of 35 cycles PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles. The total duration of treatment is up to approximately 2 years.
Recent progresses in diagnostic and therapeutic methods have significantly improved prognosis in cancer patients. However, cancer is still considered as one of the main causes of human deaths in the world. Late diagnosis in advanced tumor stages can reduce the effectiveness of treatment methods and increase mortality rate of cancer patients. Therefore, investigating the molecular mechanisms of tumor progression can help to introduce the early diagnostic markers in these patients. MicroRNA (miRNAs) has an important role in regulation of pathophysiological cellular processes. Due to their high stability in body fluids, they are always used as the non-invasive markers in cancer patients. Since, miR-363 deregulation has been reported in a wide range of cancers, we discussed the role of miR-363 during tumor progression and metastasis. It has been reported that miR-363 has mainly a tumor suppressor function through the regulation of transcription factors, apoptosis, cell cycle, and structural proteins. MiR-363 also affected the tumor progression via regulation of various signaling pathways such as WNT, MAPK, TGF-β, NOTCH, and PI3K/AKT. Therefore, miR-363 can be introduced as a probable therapeutic target as well as a non-invasive diagnostic marker in cancer patients.
Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.
A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
BACKGROUND: Non-small cell lung cancer (NSCLC) is the main type of lung cancer with high morbidity and mortality. Vascular mimicry (VM), a distinct microcirculation model in tumors that differs from classical angiogenesis, is strongly associated with poor clinical outcomes in cancer patients. miR-491-5p has been reported to prevent NSCLC progression, including proliferation, metastasis, and angiogenesis. However, the effect and mechanism of miR-491-5p on VM have not been studied in NSCLC.
METHODS: The expression of miR-491-5p was detected by quantitative reverse transcription PCR (qPCR) and fluorescence in situ hybridization (FISH). Cell counting kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) staining assays were used to examine cell growth. Tube formation assay was used to assess VM in NSCLC cells. Immunohistochemistry (IHC) and western blot were performed to detect protein expression. Immunoprecipitation was used to confirm the interaction between OTU deubiquitinase 7B (OTUD7B) and vascular endothelial growth factor A (VEGFA), and the level of ubiquitinated VEGFA. A nude mouse tumorigenesis model was used to evaluate the carcinogenic capacity of NSCLC cells in vivo. Luciferase reporter assay was used to identify the potential target of miR-491-5p.
RESULTS: MiR-491-5p was found downregulated in NSCLC tissues, and miR-491-5p deficiency was strongly associated with angiogenesis. miR-491-5p mimics suppressed cell viability, migration, and VM. Conversely, an inhibitor of miR-491-5p had the opposite effect. OTUD7B, a deubiquitinase, was identified as a downstream target of miR-491-5p. A luciferase reporter assay indicated that miR-491-5p directly binds to the 3'UTR of OTUD7B. Moreover, mimics of miR-491-5p caused a significant reduction in the OTUD7B protein in NSCLC cells, and an inhibitor of miR-491-5p stabilized the OTUD7B protein. In addition, overexpression of OTUD7B promoted cell proliferation, migration, and VM, similar to the effects of an inhibitor of miR-491-5p. Further exploration revealed that OTUD7B interacts with VEGFA and that the miR-491-5p-OTUD7B axis modulates the ubiquitination of VEGFA. The rescue experiment indicated that OTUD7B compromised the inhibitory effects of miR-491-5p on the cellular function of NSCLC cells.
CONCLUSIONS: Overall, our study first proved that miR-491-5p impedes VM by suppressing OUTD7B and promoting the ubiquitination of VEGFA. The miR-491-5p/OTUD7B axis may be a novel target for antiangiogenic therapy in NSCLC.
PURPOSE: A composition for treating osteoporosis is provided to suppress bone absorption and osteogenesis. CONSTITUTION: A composition for treating osteoporosis contains ethanol extract of horse bone and Acanthopanax koreanum shell as active ingredients. The extract of horse bone is obtained by immersing horse bone in 60-80% of ethanol solution. The Acanthopanax koreanum shell extract is obtained by immersing Acanthopanax koreanum in 80% of ethanol solution. The composition is a pharmaceutical composition or food composition. The food composition is a functional beverage.